CTRI/2024/07/070816尚未招募2/3 期
A phase 2/3 double-masked, randomized, 2 stage, multicenter study of the efficacy and safety of OCS-01 eye drops in subjects with diabetic macular edema.
Oculis Operations SÃ rl7 个研究点 分布在 1 个国家目标入组 350 人开始时间: 2024年7月30日最近更新:
试验速览
- 阶段
- 2/3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 350
- 试验地点
- 7
- 主要终点
- Mean change from baseline in BCVA (Best Corrected Visual Acuity)- Assessed using ETDRS (Early Treatment Diabetes Retinopathy Study) letters score: higher numbers on the EDTRS chart representing better visual acuity.
研究概览
简要总结
This is randomized, placebo controlled, parallel-group, phase 2/3 study to enroll approx. 30 subjects from India (Male or Female of 18 to 85 years of age with type 1 or 2 diabetes mellitus and diabetic macular edema (DME)).
The objective of this study is to demonstrate efficacy and safety of OCS-01 as compared to vehicle/placebo at Week 52. OCS-01 is a novel topical eye drop formulation with a different route of administration from the currently available therapies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- Participant and Investigator Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 85.00 Year(s)（—）
- 性别
- All
入选标准
- •1.Have a signed informed consent form before any study-specific procedures are performed.
- •2.Have DME with presence of intraretinal and/or subretinal fluid in the study eye, with CST of ≥310 µm by SD-OCT at screening (Visit 1) (as assessed by an independent reading center).
- •3.Have a documented diagnosis of Type 1 or Type 2 diabetes mellitus and an HbA1c of ≤ 10.0% prior to screening (Visit 1).
排除标准
- •1.Have macular edema considered to be because of a cause other than DME.
- •2.Have a decrease in BCVA because of causes other than DME.
- •3.Have a known history of significant macular ischemia which would prevent gain in visual acuity in the study eye.
结局指标
主要结局
Mean change from baseline in BCVA (Best Corrected Visual Acuity)- Assessed using ETDRS (Early Treatment Diabetes Retinopathy Study) letters score: higher numbers on the EDTRS chart representing better visual acuity.
时间窗: Week 52
次要结局
- Proportion of subjects with 3-line or greater gain in BCVA ETDRS letters compared with baseline.(Week 52)
研究者
研究点 (7)
Loading locations...
相似试验
尚未招募
3 期
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)NCT07303322Eurofarma Laboratorios S.A.372
招募中
3 期
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor DeficiencyNCT07266805Pharvaris Netherlands B.V.32
招募中
2 期
A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial DiseasePeripheral Arterial DiseaseNCT07318155Sirius Therapeutics Co., Ltd.104
招募中
3 期
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ-CSU2)CTRI/2025/01/079061Celldex Therapeutics, Inc.915
招募中
4 期
Sarilumab Efficacy and Safety in Adults With Early Polymyalgia RheumaticaPolymyalgia RheumaticaNCT07286214Sanofi300